Zuranolone Patent Expiration
Zuranolone is Used for treating postpartum depression. It was first introduced by Biogen Inc
Zuranolone Patents
Given below is the list of patents protecting Zuranolone, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zurzuvae | US11236121 | Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid | Aug 23, 2037 | Biogen Inc |
| Zurzuvae | US11884696 | Crystalline 19-nor C3,3-disubstituted C21-n-pyrazolyl steroid | Aug 23, 2037 | Biogen Inc |
| Zurzuvae | US10172871 | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof | Apr 17, 2034 | Biogen Inc |
| Zurzuvae | US10342810 | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof | Apr 17, 2034 | Biogen Inc |
| Zurzuvae | US9512165 | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof | Apr 17, 2034 | Biogen Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Zuranolone's patents.
Latest Legal Activities on Zuranolone's Patents
Given below is the list recent legal activities going on the following patents of Zuranolone.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 10 Sep, 2025 | US10342810 |
| transaction for FDA Determination of Regulatory Review Period | 10 Sep, 2025 | US9512165 |
| transaction for FDA Determination of Regulatory Review Period | 10 Sep, 2025 | US11236121 |
| transaction for FDA Determination of Regulatory Review Period | 10 Sep, 2025 | US10172871 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 16 Jul, 2025 | US11236121 |
| Second letter to regulating agency to determine regulatory review period | 10 Jul, 2025 | US9512165 |
| Second letter to regulating agency to determine regulatory review period | 10 Jul, 2025 | US10172871 |
| Second letter to regulating agency to determine regulatory review period | 10 Jul, 2025 | US10342810 |
| Second letter to regulating agency to determine regulatory review period | 10 Jul, 2025 | US11236121 |
| Information Disclosure Statement (IDS) Filed | 27 Jun, 2025 | US10172871 |
Zuranolone's Family Patents
